People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Biotechnology, Software / Tech, Other, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Rakuten Medical, Inc. | — | Biotechnology | Series D+ | $787.8M | $17.6M | 2019 |
| Figure Technologies, Inc. | — | Software / Tech | Series D+ | $299.9M | $2.9B | 2019 |
| Bill.Com, Inc. | — | Other | Series C | $184.6M | $44.7M | 2017 |
| 99Bill Corp | — | Other Technology | Series B | $66.5M | $822.3M | 2009 |
| Rockyou Inc | — | Other Technology | Series A | $29.8M | $326.6M | 2012 |
| Trusper Inc. | — | Other Technology | Series B | $24.1M | $487.9M | 2013 |
| Ahalife Holdings Inc. | — | Other Technology | Series A | $23.0M | $27.7M | 2013 |
| TransLattice Inc | — | Other Technology | Series A | $20.2M | $9.7M | 2013 |
| Asset Avenue, Inc. | — | Other | Series B | $19.1M | $251.6M | 2015 |
| Eaze Solutions, Inc. | — | Other Technology | Series A | $17.8M | $230.7M | 2016 |
| Billing Revolution Inc | — | Other Technology | Series A | $8.5M | $204.7M | 2011 |
David Chao at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Chao on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Hiroshi Mikitani | 2 | 3 |
| Mark Johnson | 1 | 22 |
| Rory O'Driscoll | 1 | 15 |
| Daniel Rosen | 1 | 13 |
| Nick Sturiale | 1 | 10 |
| Brian Jacobs | 1 | 9 |
| Mark Thompson | 1 | 9 |
| David Hornik | 1 | 8 |
| Adam Boyden | 1 | 7 |
| Peter Nieh | 1 | 7 |
| Lawrence Lenihan | 1 | 7 |
| Tom Mawhinney | 1 | 6 |
| Wayne Kimmel | 1 | 6 |
| Meyer Malka | 1 | 6 |
| Gen Isayama | 1 | 4 |
| Asiff Hirji | 1 | 4 |
| Matthew Wilkerson | 1 | 3 |
| Lei Zhang | 1 | 3 |
| Nicolas El Baze | 1 | 3 |
| Tom Blaisdell | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.